**Author details**

P. Kaipainen1 , T. Westermarck1 , F. Atroshi2 , M. Kaski1 and M. Iivanainen1,3

1 Rinnekoti Research Centre, FIN Espoo, Finland

2 Department of Clinical Sciences, Pharmacology & Toxicology, University of Helsinki, Finland

3 Department of Child Neurology, University of Helsinki, Finland

### **References**

[1] Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000 ;22(1):62-5.

[2] Aldenkamp A., Vigevano F., Arzimanoglou A & Covanis A. Role of valproate across the ages.Treatment of epilepsy in children. Acta neurological Scandinavica Supple‐ mentum;2006,184,1-13.

[14] Cramer, J. A., & Mattson, R. H. Valproic acid: In vitro plasma protein binding and interaction with phenytoin. Therapeutic Drug Monitoring,1979; 1(1), 105-116.

Clinical and Hematological Profiles During Valproate Treatment of Epileptic Patients with...

http://dx.doi.org/10.5772/57369

279

[15] Dean, J. C., & Penry, J. K. Valproate monotherapy in 30 patients with partial seizures.

[16] Delucchi, G. A., & Calabrese, J. R. Anticonvulsants for treatment of manic depres‐

[17] Gerstner T, Bell N, Koenig SA. Valproate-associated reversible encephalopathy in a 3-year-old girl with Pallister-Killian syndrome. Ther Clin Risk Manag. 2008 ;4(3):

[18] Gerstner T, Buesing D, Longin E, Bendl C, Wenzel D, Scheid B, Goetze G, Macke A, Lippert G, Klostermann W, Mayer G, Augspach-Hofmann R, Fitzek S, Haensch CA, Reuland M, Koenig SA. Valproic acid induced encephalopathy--19 new cases in Ger‐ many from 1994 to 2003--a side effect associated to VPA-therapy not only in young

[19] Gerstner T., Teich M., Bell N., Longin E., Dempfle CE., Brand J & König S. Valproateassociated coagulopathies are frequent and variable in children. Epilepsia, 2006; 47,

[21] Hemingway C, Leary M, Riordan G, Schlegal B, Walker K. The effect of carbamaze‐ pine and sodium valproate on the blood and serum values of children from a third-

[22] Hjelm M., Oberholzer V., Seakins J., Thomas S & Kay JDS. Valproate inhibiton of

[23] Iivanainen M & Alvarez N. (eds). Drug treatment of epilepsy in people with intellec‐ tual disability. Journal of Intellectual Disability Research. 1998; 42 (suppl. 1), 1-92.

[24] Katayama Y, Becker DP, Tamura T, Hovda DA. Massive increases in extracellular po‐ tassium and the indiscriminate release of glutamate following concussive brain in‐

[25] Koenig SA, Buesing D, Longin E, Oehring R, Häussermann P, Kluger G, Lindmayer F, Hanusch R, Degen I, Kuhn H, Samii K, Jungck A, Brückner R, Seitz R, Boxtermann W, Weber Y, Knapp R, Richard HH, Weidner B, Kasper JM, Haensch CA, Fitzek S, Hartmann M, Borusiak P, Müller-Deile A, Degenhardt V, Korenke GC, Hoppen T, Specht U, Gerstner T. Valproic acid-induced hepatopathy: nine new fatalities in Ger‐

[26] Kreuz W, Linde R, Funk M, Meyer-Schrod R, Föll E, Nowak-Göttl U, Jacobi G, Vigh Z, Scharrer I. Valproate therapy induces von Willebrand disease type I. Epilepsia.

sion. Cleveland Clinic Journal of Medicine,1989; 56(8): 756-761.

[20] Hartwig A. Cadmium and cancer. Met Ions Life Sci. 2013;11:491-507.

world environment.J Child Neurol. 1999 Nov;14(11):751-3.

Epilepsia, 1988; 29(2): 140-144.

children. Seizure. 2006 ;15(6):443-8.

urea cycle. Lancet. 1987; 923.

1992;33(1):178-84.

jury. J Neurosurg. 1990 ;73(6):889-900.

man from 1994 to 2003. Epilepsia. 2006;47, 2027-31.

645-7.

1136-43.


[14] Cramer, J. A., & Mattson, R. H. Valproic acid: In vitro plasma protein binding and interaction with phenytoin. Therapeutic Drug Monitoring,1979; 1(1), 105-116.

[2] Aldenkamp A., Vigevano F., Arzimanoglou A & Covanis A. Role of valproate across the ages.Treatment of epilepsy in children. Acta neurological Scandinavica Supple‐

[3] Antoniou T, Gough K, Yoong D, Arbess G. Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid.Clin Infect Dis. 2004,1;38(5):

[4] Bain B, England J: Normal haematological values: sex difference in neutrophil count.

[5] Ben-Menachem E., Schmidt B., Tomson T & Vajda F. Role of valproate across the ages. Treatment of epilepsy in adults. Acta neurologica Scandinavica Supplementum;

[6] Blaheta, R. A., & Cinatl, J.,Jr. Anti-tumor mechanisms of valproate: A novel role for

[7] Butkiewicz AM, Kemona H, Dymicka-Piekarska V, Matowicka-Karna J, Radziwon P, Lipska A: Platelet count, mean platelet volume and thrombopoietic indices in healthy

[8] Calleja, S., Salas-Puig, J., Ribacoba, R., & Lahoz, C. H. Evolution of juvenile myoclon‐ ic epilepsy treated from the outset with sodium valproate. Seizure: The Journal of the

[9] Chateauvieux S, Eifes S, Morceau F, Grigorakaki C, Schnekenburger M, Henry E, Di‐ cato M, Diederich M. Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway.Biochem

[10] Chen HF, Xu LP, Luo ZY, Yu ZQ, Li ZY, Cui QY, Qin LM, Ren YY, Shen HS, Tang JQ, Jin LJ, Zhu JJ, Wang J, Wang KY, Wu TQ, Wang ZY. Valproic acid-associated low fibrinogen and delayed intracranial hemorrhage: case report and mini literature re‐

[11] Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study.Epilepsia. 2004 ;45(9):1049-53. [12] Coppola G., Epifanio G., Auricchio G., Federico RR., Resicato G & Pascotto A. Plas‐ ma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. Brain & Development.

[13] Cotarlu D & Zaldman L. Valproic acid and the liver. Clinical chemistry. 1988;

an old drug. Medicinal Research Reviews,2002; 22(5), 492-511.

women and men. Thrombosis Res 2006, 118:199-204.

British Epilepsy Association,2001; 10(6), 424-427.

view. Drug Des Devel Ther. 2013,13;7:767-70.

Pharmacol. 2011,15;81(4):498-509.

2006; 28: 358-65.

34:890-897.

mentum;2006,184,1-13.

278 Pharmacology and Nutritional Intervention in the Treatment of Disease

BMJ 1975, 1:306-309.

2006,184: 14-27.

38-40.


[27] Ladds B, Thomas P, Mejia C, Hauser D. Extreme elevation of creatinine phosphoki‐ nase levels in neuroleptic malignant syndrome associated with atypical antipsychot‐ ics. Am J Psychiatry. 2009;166(1):114-5.

[41] Rao ML, Stefan H, Scheid C, Kuttler AD, Fröscher W. Serum amino acids, liver sta‐ tus, and antiepileptic drug therapy in epilepsy. Epilepsia. 1993 ;34(2):347-54

Clinical and Hematological Profiles During Valproate Treatment of Epileptic Patients with...

http://dx.doi.org/10.5772/57369

281

[42] Rosenberg, G. "The mechanisms of action of valproate in neuropsychiatric disorders: Can we see the forest for the trees?". Cellular and Molecular Life Sciences; 2007, 64

[43] Sanai T, Matsui R, Hirano T, Torichigai S, Yotsueda H, Higashi H, Hirakata H, Iida M. Successful treatment of six patients with neuroleptic malignant syndrome associ‐

[44] Sandler RM., Emberson C., Roberts GE, Voak D., Darnborough J & Heeley AF. IgM platelet autoantibody due to sodium valproate. British Journal of Medicine.1978; 2,

[46] Taher AT, Musallam KM, Nasreddine W, Perrine SP, El-Hajj TI, Beydoun A. Effects of divalproex sodium on hemoglobin level.Blood Cells Mol Dis. 2009;43(1):49-52. [47] Thurston JH & Hauhart RE. Reversal of the adverse chronic effects of the unsaturat‐ ed derivative of valproic acid - 2-n-propyl-4-pentenoic acid - on ketogenesis and liver coenzyme A metabolism by a single injection of pantothenate, carnitine and acetyl‐

[48] Verma NP, Haidukewych D. Differential but infrequent alterations of hepatic en‐ zyme levels and thyroid hormone levels by anticonvulsant drugs. Arch Neurol.

[49] Waalen J, Felitti V, Beutler E: Haemoglobin and ferritin concentrations in men and

[50] World Health Organization: Iron deficiency anaemia: assessment, prevention, and

[51] Zeller JA., Schlesinger S., Runge U & Kessler C. Influence of valproate monotherapy

on platelet activation and hematologic values. Epilepsia, 1999; 40,186-9.

ated with myoglobulinemic acute renal failure.Ren Fail. 2006;28(1):51-5.

[45] Shahidi N: Androgens and erythropoesis. NEJM 1973, 289:72.

cysteine in developing mice. Pediatric Research.1993; 33, 72-76.

women: cross sectional study. BMJ 2002, 325:137.

control; A guide for programme manager; 2001.

(16): 2090–2103.

1994 ;51(4):381-4.

1683-4.


[27] Ladds B, Thomas P, Mejia C, Hauser D. Extreme elevation of creatinine phosphoki‐ nase levels in neuroleptic malignant syndrome associated with atypical antipsychot‐

[28] Lal, H., Shearman, G. T., Fielding, S., Dunn, R., Kruse, H., & Theurer, K. Evidence that GABA mechanisms mediate the anxiolytic action of benzodiazepines:A study

[29] Lheureux PHR., Penaloza A., Zahir S & Gris Mireille. Science review:Carnitine in the treatment of valproic acid-induced toxicity-what is the evidence? Critical Care.2005;

[30] Loscher, W. Valproate: A reappraisal of its pharmacodynamic properties and mecha‐

[31] Mallet L., Babin S & Morais JA. Valproic acid-induced hyperammonemia and throm‐ bocytopenia in an elderly woman. The Annals of Pharmacotherapy. 2004; 38, 1643-7.

[32] Mazaira S. Haematological adverse effects caused by psychiatric drugs. Vertex, 2008;

[33] McQueen EG, Wardell WM. Drug displacement from protein binding: isolation of a redistributional drug interaction in vivo.Br J Pharmacol. 1971;43(2):312-24.

[34] Murakami K., Sugimoto T., Woo M., Nishida N & Muro H. Effect of L-carnitine sup‐ plementation on acute valproate intoxication. Epilepsia,1996; 37, 687-689.

[35] Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective

[36] Nilsson P, Ronne-Engstrom E, Flink R, Ungerstedt U, Carlson H, Hillered L. Epilep‐ tic seizure activity in the acute phase following cortical impact trauma in rat. Brain

[37] Pan CF, Shen MY, Wu CJ, Hsiao G, Chou DS, Sheu JR. Inhibitory mechanisms of ga‐ bapentin, an antiseizure drug, on platelet aggregation. J Pharm Pharmacol.

[38] Perucca E., Aldenkamp A., Tallis R & Kramer G. Role of valproate across the ages. Treatment of epilepsy in the elderly. Acta neurologica Scandinavica Supplementum.

[39] Perucca, E. Pharmacological and therapeutic properties of valproate: A summary af‐

[40] Rahman A, Mican LM, Fischer C, Campbell AH. Evaluating the incidence of leuko‐ penia and neutropenia with valproate, quetiapine, or the combination in children

ter 35 years of clinical experience. CNS Drugs,2002; 16(10), 695-714.

and adolescents. Ann Pharmacother. 2009 ;43(5):822-30.

with valproic acid. Neuropharmacology,1980;19(8), 785-789.

nisms of action. Progress in Neurobiology,1999; 58(1), 31-59.

monotherapy study. Epilepsia. 2008;49(3):438-45.

ics. Am J Psychiatry. 2009;166(1):114-5.

280 Pharmacology and Nutritional Intervention in the Treatment of Disease

9, 431-440.

19(82):378-86.

Res. 1994; 637: 227–232.

2007;59(9):1255-61.

2006; 184, 28-37.


**Chapter 13**

**Anti Oxidative,**

**Anti Peroxidative and**

http://dx.doi.org/10.5772/57373

**1. Introduction**

**Hepatoprotective Potential of**

Sangeeta Shukla, Neelu Sinha and Amita Jaswal

Additional information is available at the end of the chapter

*Phyllanthus amarus* **Against Anti Tb Drugs**

The liver plays an astonishing array of vital functions in the maintenance and perform‐ ance of the body. Additionally, it is also handling the metabolism and excretion of drugs and other xenobiotics from the body thereby providing protection against foreign substan‐ ces by detoxifying and eliminating them (saleem et al., 2010). Large numbers of xenobiot‐ ics are reported to be potentially hepatotoxic. Free radicals generated from the xenobiotic metabolism can induce lesions of the liver and react with the basic cellular constituents such as proteins, lipids, RNA and DNA (Ajith *et al.,* 2007). A growing international health concern is Tuberculosis caused by *Mycobacterium tuberculosis* (Abdelaal *et al.,* 2009).India is the highest TB burden country accounting for one fifth (21%) of the global incidence (WHO, 2010). The first line anti-tuberculosis drugs isoniazid (INH), rifampicin (RIF), pyrazina‐ mide (PZA) and Ethambutol(ETH)continues to be the effective drugs in the treatment of tuberculosis, however, the use of these drugs is associated with toxic reactions in tissues, particularly in the liver, leading to hepatitis (Eminzade *et al.,* 2008). This is one of the most serious adverse effects of anti-tuberculosis drugs (ATD). Liver injury or liver dysfunction is a major health problem that challenges not only health care professionals but also the pharmaceutical industry and drug regulatory agencies (saleem *et al.,* 2010). It has great capacity to detoxify and synthesize useful substances, and therefore damage to the liver has grave consequences (Devaraj *et al*., 2011). Currently, there is no effective treatment against ATD induced hepatic damage. Plants are an important component of the health

> © 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Anti Oxidative, Anti Peroxidative and Hepatoprotective Potential of** *Phyllanthus amarus* **Against Anti Tb Drugs**

Sangeeta Shukla, Neelu Sinha and Amita Jaswal

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/57373
